Erythropoiesis-stimulating agents in low-risk MDS

S. Park, K. Götze

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Patients with lower-risk myelodysplastic syndromes (MDS) are affected mainly by chronic anemia and fatigue rather than progression to acute myeloid leukemia. The main aim of treatment is to improve anemia and decrease red blood cell transfusions. Erythropoiesis-stimulating agents (ESAs) are generally first-line therapy, yielding a response in about half of the patients for around 2 years. Predictive factors of response remain non-transfusion dependence and sEPO <200 IU/L. For refractory or relapsing patients after ESA, strategies include lenalidomide alone or with ESA, azacitidine, or luspatercept. For patients with del 5q, lenalidomide is more efficient.

Original languageEnglish
Title of host publicationHematologic Malignancies
PublisherSpringer Verlag
Number of pages13
StatePublished - 2018
Externally publishedYes

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774


Dive into the research topics of 'Erythropoiesis-stimulating agents in low-risk MDS'. Together they form a unique fingerprint.

Cite this